Literature DB >> 15050966

Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus.

Jung-Hyun Choi1, Elmer Brummer, David A Stevens.   

Abstract

Micafungin, a new echinocandin, inhibits fungal cell wall beta-glucan synthesis. We postulated micafungin and host phagocytic cells could act together in damaging fungi. Using the metabolic XTT assay, micafungin alone (0.01 and 0.10 microg/ml) inhibited Aspergillus fumigatus germlings by 48% and 61%, respectively. Polymorphonuclear neutrophils (PMNs) inhibited germlings by 53%. Micafungin at 0.01 or 0.10 microg/ml and PMNs resulted in additive inhibition, 82% and 99%, respectively. Monocyte-derived macrophage (MDM) monolayers inhibited germling growth by 66%; micafungin (0.01 or 0.10 microg/ml) alone inhibited by 32% and 42%, respectively. MDMs and micafungin (0.01 or 0.10 microg/ml) caused an additive inhibition of growth, 85% and 95%, respectively. Hyphae were generated by incubation of conidia for 24 h with or without micafungin. PMNs alone, added to hyphae, inhibited growth by 19% in the subsequent 20 h. Hyphae generated in the presence of micafungin (0.10 microg/ml) and subsequently cultured with micafungin for 24 h inhibited growth by 64%. PMNs plus micafungin resulted in 82% inhibition. Monocytes alone inhibited hyphal growth by only 5%. Hyphae produced in the presence of micafungin (0.01 microg/ml) and incubated again with micafungin for 24 h inhibited growth by 47%; combination with monocytes resulted in 62% inhibition. These data indicate that micafungin inhibits growth of tissue forms of A. fumigatus, and phagocytes and micafungin together have an additive effect. These findings support the thesis that the greater efficacy of micafungin in vivo compared with in vitro could be due to combined effect of phagocytic cells and micafungin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050966     DOI: 10.1016/j.micinf.2003.12.010

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  7 in total

1.  Endogenous aspergillus endophthalmitis after kidney transplantation.

Authors:  Huan-Huan Cheng; Yong Ding; Min Wu; Cui-Cui Tang; Ri-Jia Zhang; Xiao-Feng Lin; Jin-Tang Xu
Journal:  Int J Ophthalmol       Date:  2011-10-18       Impact factor: 1.779

2.  Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae.

Authors:  Gregory A Lamaris; Russell E Lewis; Georgios Chamilos; Gregory S May; Amar Safdar; Thomas J Walsh; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

3.  Interaction of platelets and anidulafungin against Aspergillus fumigatus.

Authors:  Susanne Perkhofer; Barbara Striessnig; Bettina Sartori; Barbara Hausott; Helmut W Ott; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

4.  Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Tin Sein; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

5.  Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Kieren A Marr; Wendi M Lau; David P Facklam; Voravit Ratanatharathorn; Cornelia Becker; Andrew J Ullmann; Nita L Seibel; Patricia M Flynn; Jo-Anne H van Burik; Donald N Buell; Thomas F Patterson
Journal:  J Infect       Date:  2006-05-06       Impact factor: 6.072

6.  Comparison of echinocandin antifungals.

Authors:  Gregory Eschenauer; Daryl D Depestel; Peggy L Carver
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

7.  In vivo Activity of Copper(II), Manganese(II), and Silver(I) 1,10-Phenanthroline Chelates Against Candida haemulonii Using the Galleria mellonella Model.

Authors:  Rafael M Gandra; Pauraic McCarron; Livia Viganor; Mariana Farias Fernandes; Kevin Kavanagh; Malachy McCann; Marta H Branquinha; André L S Santos; Orla Howe; Michael Devereux
Journal:  Front Microbiol       Date:  2020-03-24       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.